A Phase 4 interventional study of Celestone + placebo and Celestone + Celestone in Preterm Birth, Premature Birth and Complication of Prematurity, sponsored by McMaster University. Recruiting at 25 sites in Canada. Open to female participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-01-07.
Sponsored by McMaster University · Phase 4, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 139 studies in Premature Birth with a site in Canada — 26 open to participants now, 34 under way, 2 of them phase 3. Premature Birth · Canada.
Among the 139 studies in Premature Birth with a site in Canada, this one is the 2nd largest by planned enrollment of the 106 interventional ones that give a count, is one of 7 that started in 2023, is one of 5 in phase 4, reaches primary completion later than 18 of the 33 other live ones, and was the 111th registered.
2,557 studies on the registry are indexed under Premature Birth; 504 are open to participants now.
Browse Premature Birth studies →26 of the 139 studies in Premature Birth with a site in Canada are open now. Recruiting first, the newest first:
Centre hospitalier de l'Université de Montréal (CHUM) · Sites in Canada
Ages 18+ · Women only
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages up to 29 wk
Michelle Baczynski · Sites in Canada, United States, Denmark
Ages 25 wk–29 wk
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 28 wk–32 wk
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 318 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 226 (71%) stop at 75 or younger; 243 take children under 18; 104 take healthy volunteers.
This study: 18 Years to 55 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
139 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 17 · Phase 3 17 · Phase 4 5
First in 1998; this study’s year is marked. 7 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 3,254 is above the median of 84 across 1,670 interventional studies indexed under Premature Birth.
Median enrollment 80 across the 106 interventional studies, 144 across the 33 observational. Of the 78 that completed or were terminated, 9 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 139 have an industry lead sponsor. The 10 most frequent:
McMaster University is the lead sponsor of 742 studies on the registry; 127 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 3 (43%) have results posted.
McMaster University has 7 studies filed under Premature Birth — fewer than ten, so there is no comparison to draw.
5 of the studies in Premature Birth with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05114096McMaster UniversitySingle Dose of Antenatal Corticosteroids for Pregnancies at Risk of Preterm Delivery (SNACS) | 2026-12-31 |
| NCT06823115Indiana UniversityAssessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0 | 2027-01 |
| NCT07732257McGill University Health Centre/Research Institute of the McGill University Health CentreWireless MicroPremVitals Button Sensor in the NICU | 2027-01-30 |
| NCT05213806IWK Health CentreWithHolding Enteral Feeds Around Blood Transfusion (International) | 2027-03-31 |
| NCT07262385University of British ColumbiaCalmer Brains in Very Preterm Infants | 2027-04 |
Add all 5 to your calendar (.ics) → With an account.
Among the 139 studies in Premature Birth with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Antenatal corticosteroids (ACS) reduce the risks of neonatal death and morbidities in preterm infants, such as respiratory distress syndrome.
The standard of care for pregnant people at risk of preterm birth includes 2 doses of Celestone (for a total of 24 mg in Canada, or 22.8 mg in Australia) to accelerate fetal lung maturity.
The investigators plan to conduct a randomized controlled trial to determine whether half the usual dose (12 mg in Canada, or 11.4 mg in Australia) of Celestone is non-inferior to the standard double doses.
Preterm infants are at risk of mortality and morbidity. Antenatal corticosteroids (ACS) reduce the risks of neonatal death and morbidities, such as respiratory distress syndrome.
The standard of care for pregnant people at risk of preterm birth includes 2 doses of Celestone to accelerate fetal lung maturity (total 24 mg in Canada, 22.8 mg in Australia). There are no published clinical trial data on the benefits or risks of a single dose of antenatal corticosteroid vs. standard double doses (Ninan et al JOGC 2020).
Pregnant people at 22 weeks and 0 days to \< 34 weeks and 6 days' gestation at risk of preterm birth with a singleton or twin gestation who have received the first dose of Celestone and consented to the trial will be randomized to receive approximately 24 hours later either an experimental placebo injection (of normal saline) or the standard double dose of Celestone to determine whether the intervention is non-inferior for the primary outcome of a composite of perinatal mortality or substantial morbidity.
Please note: Based on Health Canada's' guidance the study phase is 'Other: Off-Label use'. However, on the clincaltrial.gov record, 'Phase 4' is selected as this is the most relevant phase and there is no option to select 'Other'.
Please note: McMaster University, Canada is the Canadian Regulatory Sponsor and Overall Sponsor, and the University of Adelaide Australia is the Australian Sponsor.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Having already received the first dose of Celestone as part of eligibility criteria, participants randomized to the experimental "Single-Dose" arm will receive a similar appearing placebo injection.
Drug: Celestone + placebo
Having already received the first dose of Celestone as part of eligibility criteria, participants randomized to the "Double-Dose" arm will receive the standard 2nd dose of Celestone injected intramuscularly (i.e. they will receive the standard double-dose regimen).
Drug: Celestone + Celestone
After the first intramuscular injection of Celestone, participants randomized to the "Placebo Comparator" group will receive 1 intramuscular injection of placebo.
Drug page: BetamethasoneStudies of BetamethasoneBetamethasone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
After the first intramuscular injection of Celestone, participants randomized to the "Active Comparator" group will receive 1 intramuscular injection of Celestone.
Perinatal Mortality or Substantial Neonatal Morbidity
Fetal death post-randomization or in hospital neonatal death OR =\> 1 of respiratory morbidity (requiring surfactant \<=48 hrs of life), severe intraventricular hemorrhage (distending/beyond the ventricles, i.e. Grade 3 or 4), or severe bowel problem (necrotizing enterocolitis, Stage 2 or 3)
Time frame: approximately 1 month
Death or neurosensory/developmental impairment at 24 months
Death or neurosensory/developmental impairment at 24 months (+/- 6 months; accounting for gestation at birth), mood (anxiety/depression), behavior (aggression), etc as assessed by: 1. Ages and Stages Questionnaire-3 (ASQ) 2. Child Behavior Checklist: 4 subscales 3. Physician diagnosis of cerebral palsy (parent report).
Time frame: approximately 24 months
Number of babies who received intubation and duration of invasive mechanical ventilation
Number of babies who received intubation and duration of invasive mechanical ventilation
Time frame: approximately up to first 6 months of life
Number of babies who received, and duration of, supplemental oxygen (after resuscitation) and other ventilatory support
Number of babies who received, and duration of, supplemental oxygen (after resuscitation) and other ventilatory support
Time frame: approximately up to first 6 months of life
Number of babies with respiratory distress after the initial resuscitation/stabilization and main cause
Number of babies with respiratory distress after the initial resuscitation/stabilization and main cause (such as respiratory distress syndrome, pneumothorax/pneumomediastinum, pneumonia, transient tachypnea of the newborn, meconium aspiration syndrome, persistent pulmonary hypertension of the newborn)
Time frame: approximately 1 month
Number of babies with Respiratory distress after the initial resuscitation/stabilization and main cause
Respiratory distress after the initial resuscitation/stabilization and main cause (such as respiratory distress syndrome, pneumothorax/pneumomediastinum, pneumonia, transient tachypnea of the newborn, meconium aspiration syndrome, persistent pulmonary hypertension of the newborn),
Time frame: approximately at birth
Number of babies with hypoglycemia
Number of babies with hypoglycemia (low plasma glucose \< 2.6 mmol/L between 30 minutes and 48 hours of life)
Time frame: 48 hours
Number of babies with neonatal sepsis
Number of babies with neonatal sepsis within 7 days of birth, defined as a positive (bacterial, viral or fungal): blood culture or cerebrospinal fluid culture (or gram stain) or urine culture by sterile collection.
Time frame: 7 days
Number of babies with severe retinopathy of prematurity needing treatment
Number of babies with severe retinopathy of prematurity defined as requiring vascular endothelial growth factor (VEGF) or laser or cryotherapy per the local guidelines
Time frame: approximately first few months of life
Number of babies with patent ductus arteriosus (PDA) needing a closure procedure (surgery or device)
Number of babies with patent ductus arteriosus (PDA) needing a closure procedure (surgery or device)
Time frame: up to 12 weeks after birth
Anthropometry at birth and at 24 months corrected age
Weight (in grams), length (in centimeters), and head circumference (in centimeters) for birth week as ACS can impact growth
Time frame: at birth and at 24 months corrected age
Number of babies with severe late brain injury
Periventricular leukomalacia \[PVL\], i.e. cystic changes in white matter or porencephalic cysts or white matter changes diagnosed by ultrasound or MRI.
Time frame: up to 20 weeks postnatal
Number of babies with chronic lung disease
Late respiratory morbidity, bronchopulmonary dysplasia (BPD), defined as requiring respiratory support or supplemental oxygen \> 36 completed weeks' corrected gestation.
Time frame: approximately up to first 6 months of life
Apgar score and cord blood pH
Apgar score (at 1 and 5 min) and lowest cord blood pH, regardless of whether arterial or venous.
Time frame: approximately at birth
Length of stay in special care or an intensive care setting
Length of stay in an intensive care setting such as the neonatal intensive care unit (NICU).
Time frame: approximately up to first 6 months of life
Use of postnatal corticosteroids
Use of systemic (intravenous or oral) postnatal corticosteroids and type (e.g. hydrocortisone, dexamethasone).
Time frame: up to 20 weeks postnatal
Number of babies with longterm health care outcomes
Number of babies with reported longterm health care outcomes after initial hospital, such as hospitalizations, and other health care use.
Time frame: approximately 5 -10 years
Number of babies with longterm education outcomes
Number of babies with reported longterm education or non-health data outcomes, collected through database linkage where possible.
Time frame: approximately 5 -10 years
Number of participants with fetal death post-randomization or in hospital neonatal death OR => 1 of respiratory morbidity, severe intraventricular hemorrhage , or severe bowel problem
Fetal death post-randomization or in hospital neonatal death OR =\> 1 of respiratory morbidity (requiring surfactant \<=48 hrs of life), severe intraventricular hemorrhage (distending/beyond the ventricles, i.e. Grade 3 or 4), or severe bowel problem (necrotizing enterocolitis, Stage 2 or 3)
Time frame: approximately 1 month
Plan to share: No — An IPD is planned with trial leaders of another half dose Celestone study.
Started Jul 2023 (actual). Primary completion is estimated for Dec 2026, 41 months after the start.
Of 54 non-industry phase 4 interventional studies under Premature Birth, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 60. This study's planned 41 months is above that.
Counting every sponsor, half of 54 studies reached it within 25 months; a quarter within 13 and three quarters within 60.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.